Combination Therapy Plus Fluvastatin Improves Hep C Outcome | Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Menu Search
Previous

Hepatitis C Hopeful PPI-461 Getting Good Marks in Phase 1b Trial

Back to News Homepage
Next

Bristol-Myers Experimental Cocktail Bests Hepatitis C Treatment

Combination Therapy Plus Fluvastatin Improves Hep C Outcome

The Editors at Hepatitis Central
April 7, 2011

Print this page

Whether or not a person has metabolic syndrome, new research shows that adding fluvastatin to standard Hepatitis C combination therapy improves response rates.

FLUVASTATIN ENHANCES CHRONIC HEPATITIS C TREATMENT RESPONSE IN COMBINATION WITH PEGYLATED INTERFERON-ALPHA AND RIBAVIRIN

Well-known statin could be recycled as HCV therapy supplement

Berlin, Germany, Thursday 31 March 2011: /PRNewswire/ — New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin – commonly used as a cholesterol-lowering treatment – in patients with chronic hepatitis C (HCV).1

Patients had improved early and sustained virological response (EVR and SVR) when treated with the current standard of care – pegylated Interferon-alpha and ribavirin (PegIFNα/RBV) – and fluvastatin. The results show patients receiving fluvastatin and PegIFNα/RBV achieve higher rates of EVR and SVR – 75.96% and 63.46% – to those receiving placebo and PegIFNα/RBV – 61.9% and 49.52% respectively.

Continue reading this entire article:
http://multivu.prnewswire.com/mnr/prne/easl/48894/

No Comments - be the first!
Share
Share
Previous

Hepatitis C Hopeful PPI-461 Getting Good Marks in Phase 1b Trial

Back to News Homepage
Next

Bristol-Myers Experimental Cocktail Bests Hepatitis C Treatment

Requirements for using and reposting articles

Comments

HepatitisCentral.com provides information regarding hepatitis and liver disease. Comments are available to the community in order to discuss these topics and obtain answers to questions through community members. The Editors at HepatitisCentral.com will not be responding to questions or comments posed in article comments.